SEC Form 4 · accession 0001209191-17-057052
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
John F Crowley
Officer — Chairman & CEO · Director
Period of report
Oct 12, 2017
Accepted (ET)
Oct 16, 2017 · 9:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 12, 2017 | M | 380,000 | $14.2495 | A | 708,001 | D | |
| Common StockF3 | Oct 12, 2017 | S | 380,000 | $14.2495 | D | 328,001 | D | |
| Common StockF4 | Oct 13, 2017 | M | 22,160 | $14.7503 | A | 350,161 | D | |
| Common StockF5 | Oct 13, 2017 | S | 22,160 | $14.7503 | D | 328,001 | D | |
| Common Stock | Oct 16, 2017 | M | 47,135 | $14.75 | A | 375,136 | D | |
| Common Stock | Oct 16, 2017 | S | 47,135 | $14.75 | D | 328,001 | D | |
| Common Stock | holding | — | — | — | 64,895 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $6.45 | Oct 12, 2017 | M | 5,783 | D | Feb 15, 2016 | Feb 15, 2022 | Common Stock | 5,783 | 131,024 | D |
| Stock Options (right to buy) | $4.38 | Oct 12, 2017 | M | 13,622 | D | Jun 4, 2016 | Jun 4, 2022 | Common Stock | 13,622 | 136,378 | D |
| Stock Options (right to buy) | $3.53 | Oct 12, 2017 | M | 3,462 | D | Jan 28, 2017 | Jan 28, 2023 | Common Stock | 3,462 | 161,538 | D |
| Stock Options (right to buy) | $2.52 | Oct 12, 2017 | M | 165,000 | D | Jun 18, 2017 | Jun 18, 2023 | Common Stock | 165,000 | 0 | D |
| Stock Options (right to buy) | $3.19 | Oct 12, 2017 | M | 192,133 | D | Jan 3, 2015 | Jan 3, 2024 | Common Stock | 192,133 | 20,972 | D |
| Stock Options (right to buy) | $3.53 | Oct 13, 2017 | M | 22,160 | D | Jan 28, 2017 | Jan 28, 2023 | Common Stock | 22,160 | 139,378 | D |
| Stock Options (right to buy) | $3.53 | Oct 16, 2017 | M | 47,135 | D | Jan 28, 2017 | Jan 28, 2023 | Common Stock | 47,135 | 92,243 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F5This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Remarks
Shares were sold to fund the "Megan K. Crowley 2016 Special Needs Trust", a trust for the benefit of Mr. Crowley's child, with the balance of the proceeds used for general estate planning purposes. The total shares sold represented less than 2% of Mr. Crowley's holdings of securities of the company.